Merus (NASDAQ:MRUS) Shares Purchased by Algert Global LLC

Algert Global LLC raised its position in Merus (NASDAQ:MRUS - Free Report) by 15.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 153,724 shares of the biotechnology company's stock after purchasing an additional 20,401 shares during the quarter. Algert Global LLC owned about 0.22% of Merus worth $7,680,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. nVerses Capital LLC lifted its stake in Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 1,500 shares in the last quarter. US Bancorp DE acquired a new stake in Merus in the 3rd quarter valued at about $103,000. SG Americas Securities LLC purchased a new position in Merus in the first quarter valued at $108,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Merus by 24.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company's stock valued at $118,000 after buying an additional 489 shares in the last quarter. Finally, Farallon Capital Management LLC purchased a new stake in Merus during the 2nd quarter worth about $237,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on MRUS shares. Guggenheim increased their price objective on Merus from $93.00 to $111.00 and gave the company a "buy" rating in a report on Tuesday, October 1st. HC Wainwright reiterated a "buy" rating and issued a $85.00 price target on shares of Merus in a research note on Friday, November 1st. UBS Group started coverage on shares of Merus in a report on Thursday, October 24th. They set a "buy" rating and a $72.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $85.00 target price on shares of Merus in a research report on Wednesday. Finally, The Goldman Sachs Group assumed coverage on shares of Merus in a research report on Thursday. They issued a "buy" rating and a $73.00 price target for the company. One equities research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $85.45.

Merus Price Performance

Shares of MRUS stock traded up $1.14 during trading hours on Friday, reaching $45.49. 682,360 shares of the company's stock were exchanged, compared to its average volume of 470,824. Merus has a 1 year low of $22.26 and a 1 year high of $61.61. The company has a market cap of $3.11 billion, a P/E ratio of -11.52 and a beta of 1.12. The company's 50 day moving average is $50.39 and its two-hundred day moving average is $51.81.

Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $11.77 million for the quarter, compared to analysts' expectations of $9.11 million. As a group, analysts predict that Merus will post -3.89 EPS for the current fiscal year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.